

Monoclonal Antibody to Gastrin - Ig Fraction

Alternate names:	GAS, GAST
Catalog No.:	AM32097PU-N
Quantity:	0.1 mg
Concentration:	0.1 mg/ml
Background:	Amidated Gastrin-17 is a biologically and physiologically important molecule among the family of the gastrin peptides. Amidated gastrin-17 is the most powerful gastrin peptide in the feedback control mechanism of the acid secretion and output from the parietal cells in the gastric corpus. This peptide is solely synthesized and secreted into the circulation by the so called G cells ("gastrin cells") in the gastric antrum. A positive immunohistochemical reaction for gastrin-17 is a sign of a highly differentiated gastrin-secreting cell and normal antral mucosa. In atrophic gastritis, the normal antral (pyloric) glands and gastrin-17 synthesizing cells disappear. Metaplastic pyloric glands (pseudopyloric metaplasia) do not contain immunopositive gastrin-17 cells.
Uniprot ID:	P01350
NCBI:	NP_000796.1
GeneID:	2520
Host / Isotype:	Mouse / IgG1
Clone:	G52C7.1
Immunogen:	Synthetic (modified) Gastrin-17 coupled to thyroglobulin. Hybridoma produced by fusion between myeloma cells and Balb/c spleen cells.
Format:	State: Liquid Ig fraction Buffer System: PBS Preservatives: 0.09 % Sodium Azide Stabilizers: 1.0% BSA
Applications:	Enzyme Immunoassays. Immunohistochemistry on Paraffin Sections. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Specificity:	The antibody Clone <i>G52C7.1</i> is specific to Gastrin-17 with no crossreactivity to Gastrin-34 or Cholecystokinin.
Species Reactivity:	Tested: Human.
Storage:	Store the antibody undiluted at 2-8°C. Shelf life: one year from despatch.
General Readings:	1. Varis K. Surveillance of pernicious anemia. In Precancerous Lesions of the Gastrointestinal Tract. Scherlock P, Morson PC, Barbara L, Veronesi U (eds), Raven Press,

New York, 189-194, 1983.

2. Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. *Int J Cancer*. 1985 Feb 15;35(2):173-7. PubMed PMID: 3871738.

3. Hallissey MT, Dunn JA, Fielding JW. Evaluation of pepsinogen A and gastrin-17 as markers of gastric cancer and high-risk pathologic conditions. *Scand J Gastroenterol*. 1994 Dec;29(12):1129-34. PubMed PMID: 7886402.

4. Sipponen P, Valle J, Varis K, Kekki M, Ihamäki T, Siurala M. Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. *Scand J Gastroenterol*. 1990 May;25(5):513-9. PubMed PMID: 2359980.